Simon Kohl

R&D

In a new episode, Simon Kohl discusses Latent Labs’ emergence from stealth, as well as protein design and drug discovery acceleration in more detail.

News

Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.